The Readout Loud

When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?

Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?

Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?

Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?

Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?

Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?

What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?

Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?

Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?

Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?

Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?

Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?

Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?

Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?

Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?

Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?

Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.

Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?

Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?

How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?